Zelgen(688266)2025-01-17 09:35Revenue Expectations - The company expects 2024 revenue to be between 517.93 million and 549.88 million CNY, representing a year-on-year increase of 34.03% to 42.30%[2]. - The increase in revenue is primarily due to the steady promotion of Donafenib tablets and an expanded market coverage leading to increased sales[4]. Net Loss Projections - The projected net loss attributable to the parent company for 2024 is between 163.90 million and 109.83 million CNY, a reduction in loss of 114.68 million to 168.75 million CNY compared to the previous year[2]. - The expected net loss attributable to the parent company after deducting non-recurring gains and losses for 2024 is between 197.97 million and 132.54 million CNY, a reduction in loss of 150.78 million to 216.21 million CNY compared to the previous year[2]. Research and Development - The company has continued to advance new drug research and development, resulting in a year-on-year decrease in overall R&D expenses due to the focus on core product development[5]. Sales and Financial Performance - Sales expenses as a percentage of drug sales revenue have decreased year-on-year, contributing to the expected reduction in losses for 2024[5]. - Interest income from bank deposits has increased year-on-year, further supporting the company's financial outlook[5]. Financial Reporting - The financial data provided is preliminary and has not been audited by registered accountants, with the final figures to be disclosed in the audited 2024 annual report[6][7].